Table 5.
Risk factors associated with 21-day mortality in patients with P. mirabilis bloodstream infectionsb
| Variable | No. of patients |
P | OR (95% CI) | |
|---|---|---|---|---|
| Nonsurvivors (n = 30) | Survivors (n = 69) | |||
| Univariate analysis | ||||
| Demographics | ||||
| Male sex | 19 (63.3) | 43 (62.3) | 0.92 | 1.04 (0.39–2.83) |
| Mean age (yr ± SD) | 63 ± 21 | 61 ± 18 | 0.68 | |
| Source of infection | ||||
| Urinary tract | 21 (70) | 42 (60.8) | 0.38 | 1.50 (0.55–4.28) |
| Lower respiratory tract | 2 (6.7) | 2 (2.9) | 0.38 | 2.39 (0.16–34.19) |
| Surgical wound | 4 (13.3) | 1 (1.4) | 0.01 | 10.46 (0.95–522.45) |
| Central venous catheter | 0 | 5 (7.2) | 0.13 | |
| Biliary tract | 2 (6.7) | 3 (4.3) | 0.62 | 1.57 (0.12–14.44) |
| Unknown | 8 (26.6) | 16 (23.1) | 0.71 | 1.20 (0.38–3.52) |
| Comorbidities | ||||
| Liver disease | 5 (16.7) | 9 (13.1) | 0.63 | 1.33 (0.31–4.96) |
| Chronic renal insufficiency | 9 (30) | 16 (23.2) | 0.47 | 1.41 (0.47–4.05) |
| Diabetes mellitus | 7 (23.3) | 17 (24.6) | 0.88 | 0.93 (0.28–2.77) |
| Hematological malignancy | 7 (23.3) | 3 (4.3) | 0.04 | 6.69 (1.35–42.37) |
| Solid tumor | 16 (53.3) | 15 (21.7) | 0.01 | 4.11 (1.48–11.36) |
| Charlson index (median [range]) | 3 (1–7) | 2 (0–11) | 0.24 | |
| History | ||||
| Previous surgery | 13 (43.3) | 33 (47.8) | 0.68 | 0.83 (0.31–2.15) |
| Previous antibiotic therapy | 14 (46.6) | 39 (56.5) | 0.36 | 0.67 (0.25–1.73) |
| Prior hospitalization | 19 (63.3) | 38 (55.1) | 0.44 | 1.40 (0.53–3.79) |
| Corticosteroid therapy | 10 (33.3) | 20 (28.9) | 0.66 | 1.25 (0.43–3.34) |
| Epidemiological category | ||||
| HCA BSI detected ≥48 h postadmission | 25 (83.3) | 57 (82.6) | 0.93 | 1.05 (0.30–4.22) |
| HCA BSI detected <48 h postadmission | 4 (13.3) | 7 (10.1) | 0.64 | 1.36 (0.26–5.89) |
| Community-acquired BSI | 1 (3.3) | 5 (7.2) | 0.45 | 0.44 (0.01–4.22) |
| Ward at BSI onset | ||||
| Medicine | 19 (63.3) | 36 (52.2) | 0.30 | 1.58 (0.60–4.25) |
| Surgery | 3 (10) | 19 (27.5) | 0.05 | 0.29 (0.05–1.13) |
| Intensive care unit | 8 (26.7) | 14 (20.3) | 0.48 | 1.42 (0.45–4.26) |
| Clinical presentation | ||||
| Mean APACHE III score (median [range])a | 49 (10–88) | 35 (3–118) | 0.02 | |
| Septic shock | 17 (56.6) | 13 (18.8) | <0.001 | 5.63 (1.98–16.04) |
| Microorganism related | ||||
| Multidrug resistance | 18 (60) | 18 (26.1) | 0.001 | 4.25 (1.56–11.65) |
| Treatment-related IIAT | 16 (53.3) | 5 (7.2) | <0.001 | 14.62 (4.10–57.81) |
| Multivariate analysis | ||||
| Presentation with septic shock | <0.001 | 12.97 (3.22–52.23) | ||
| IIAT | 0.001 | 9.85 (2.67–36.25) | ||
| MDR-resistant P. mirabilis isolate | 0.008 | 6.62 (1.64–26.68) | ||
a
Calculated on the basis of chart data relative to the 24 h following BSI onset. When data were missing for one variable, that variable was assigned a value of 0, indicating that it was within normal limits. If more than one variable was missing, the case was excluded from the study.
b
Abbreviations: BSI, bloodstream infection; HCA, health care associated (as defined in Materials and Methods); IIAT, inadequate initial antimicrobial therapy; MDR, multidrug resistant.